DMC Group LLC Sells 651 Shares of DexCom, Inc. (NASDAQ:DXCM)

DMC Group LLC trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 11.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,231 shares of the medical device company’s stock after selling 651 shares during the quarter. DMC Group LLC’s holdings in DexCom were worth $407,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Versant Capital Management Inc bought a new stake in DexCom in the 4th quarter valued at $25,000. Riverview Trust Co lifted its stake in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the period. RPg Family Wealth Advisory LLC acquired a new stake in DexCom during the third quarter worth about $57,000. Covestor Ltd increased its stake in DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares during the period. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after acquiring an additional 265 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.30% of the stock is currently owned by corporate insiders.

DexCom Stock Performance

DexCom stock opened at $86.43 on Thursday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The stock has a 50-day simple moving average of $80.00 and a 200 day simple moving average of $76.52. The stock has a market capitalization of $33.76 billion, a price-to-earnings ratio of 51.75, a P/E/G ratio of 2.23 and a beta of 1.12.

Analyst Ratings Changes

DXCM has been the topic of several recent research reports. Raymond James decreased their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Royal Bank of Canada dropped their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein lifted their target price on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Finally, Citigroup increased their price target on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus price target of $99.29.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.